Cell based Assay Market to grow at CAGR of 6.3% by 2024 according to new research report
The cell-based assays market is projected to reach USD 18.9 billion by 2024 from USD 13.9 billion in 2019, at a CAGR of 6.3%.
(EMAILWIRE.COM, July 18, 2019 ) The Report"Cell based Assay Market by Product (Reagents, Microplates, Cell Lines, Assay Kits, Instruments, Services), Application (Drug Discovery, Research), End User (CROs, Biopharma Companies, Research Institutes), Geography - Global Forecast to 2024"
The cell-based assays market is projected to reach USD 18.9 billion by 2024 from USD 13.9 billion in 2019, at a CAGR of 6.3%.
The growth of this market is majorly driven by the growing preference for cell-based assays, increasing research funding, and the growth in the number of drug discovery activities. However, the high cost of instruments and restrictions on reagent use are the major factors restraining the growth of this market.
Download a FREE Pdf Broucher @:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269
Key Market Players
Some of the prominent players in the cell-based assays market are Thermo Fisher Scientific, Inc. (US), Danaher Corporation (Beckman Coulter, Inc.) (US), Becton, Dickinson and Company (US), GE Healthcare (US), Merck KGaA (Germany), Lonza Group (Switzerland), PerkinElmer, Inc. (US), Charles River Laboratories, Inc. (US), Cell Signaling Technologies (US), Cisbio (US), Cell Biolabs, Inc. (US), and Promega Corporation (US).
Thermo Fisher Scientific is the leading player in the cell-based assays market.
The company offers a range of assay kits and cell lines used in cell-based assays. The company‘s large share in this market can be attributed to its extensive product portfolio and strong sales & distribution network. Thermo Fisher focuses on developed and emerging markets in order to generate a significant amount of its revenue. The company registered 57.7% of its total revenue from the US and China together. In order to maintain its leading position in the market, the company also invests 3–5% of its total revenue on R&D.
Recent developments:
• In 2019, Danaher launched its ClearLLab 10C System for clinical Flow Cytometry labs. The new system includes the first 10-color CE-IVD panels of immunophenotyping reagents for both lymphoid and myeloid lineages. The tubes utilize the DURA Innovations dry reagent technology for panels, which requires no refrigeration.
• In 2018, GE Healthcare is planning to open a new testing center in Sweden to advance its manufacturing and research capabilities.
Get Sample Report with all Graphs & Charts related to it @: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=119917269
Media Contact
- Mr. Shelly Singh
- raviraj.tak@marketsandmarkets.com